神经病理性疼痛
神经炎症
医学
痛觉超敏
药理学
痛觉过敏
神经科学
小胶质细胞
慢性疼痛
神经学
麻醉
受体
伤害
内科学
炎症
心理学
精神科
作者
Simona Denaro,Lorella Pasquinucci,Rita Turnaturi,Cristiana Alberghina,Lucia Longhitano,Sebastiano Giallongo,Giuliana Costanzo,Salvatore Spoto,Margherita Grasso,Agata Zappalà,Giovanni Li Volti,Daniele Tibullo,Nunzio Vicario,Rosalba Parenti,Carmela Parenti
标识
DOI:10.1007/s12035-023-03717-w
摘要
Neuropathic pain is one of the most debilitating forms of chronic pain, resulting from an injury or disease of the somatosensory nervous system, which induces abnormal painful sensations including allodynia and hyperalgesia. Available treatments are limited by severe side-effects and reduced efficacy in the chronic phase of the disease. Sigma-1 receptor (σ1R) has been identified as a chaperone protein, which modulate opioid receptors activities and the functioning of several ion channels, exerting a role in pain transmission. As such, it represents a druggable target to treat neuropathic pain. This study aims at investigating the therapeutic potential of the novel compound (+)-2R/S-LP2, a σ1R antagonist, in reducing painful behaviour and modulating the neuroinflammatory environment. We showed that repeated administration of the compound significantly inhibited mechanical allodynia in neuropathic rats, increasing the withdrawal threshold as compared to CCI-vehicle rats. Moreover, we found that (+)-2R/S-LP2-mediated effects resolve the neuroinflammatory microenvironment by reducing central gliosis and pro-inflammatory cytokines expression levels. This effect was coupled with a significant reduction of connexin 43 (Cx43) expression levels and gap junctions/hemichannels mediated microglia-to-astrocyte communication. These results suggest that inhibition of σ1R significantly attenuates neuropathic pain chronicization, thus representing a viable effective strategy.
科研通智能强力驱动
Strongly Powered by AbleSci AI